Nuclear factor-κB p65 mediates tumor necrosis factor α-induced nuclear translocation of telomerase reverse transcriptase protein

Cancer Research

Volumn 63, Issue 1, 2003, Pages 18-21

  Akiyama, Masaharu ^a   Hideshima, Teru ^a   Hayashi, Toshiaki ^a   Tai, Yu Tzu ^a   Mitsiades, Constantine S ^a   Mitsiades, Nicholas ^a   Chauhan, Dharminder ^a   Richardson, Paul ^a   Munshi, Nikhil C ^a,b   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; I KAPPA B; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; RNA DIRECTED DNA POLYMERASE; SYNAPTOTAGMIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL NUCLEUS; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; CANCER CELL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; TELOMERE;

CELL NUCLEUS; DNA-BINDING PROTEINS; HUMANS; NF-KAPPA B; RECOMBINANT PROTEINS; TELOMERASE; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037207872     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Harley, C. B. Telomerase is not an oncogene. Oncogene, 21: 494-502, 2002.
2. Herbert, B. S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA, 96: 14276-14281, 1999.
3. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Karachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., and Weinberg, R. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
4. Kyo, S., and Inoue, M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene, 21: 688-697, 2002.
5. Kang, S. S., Twon, T., Kwon, D. Y., and Do, S. L. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem., 274: 13085-13090, 1999.
6. Liu, K., Hodes, R. J., and Weng, N. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol., 166: 4826-4830, 2001.
7. Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y. T., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P., Munshi, N. C., and Anderson, K. C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res., 62: 3876-3882, 2002.
8. Yang, Y., Chen, Y., Zhang, C., Huang, H., and Weissman, S. M. Nucleolar localization of hTERT protein is associated with telomerase function. Exp. Cell Res., 277: 201-209, 2002.
9. Etheridge, K. T., Banik, S. S. R., Armbruster, B. N., Zhu, Y., Terns, B. M., Terns, M. P., and Counter, C. M. The nucleolar localization domain of the catalytic subunit of human telomerase. J. Biol. Chem., 277: 24764-24770, 2002.
10. Wong, J. M. Y., Kusdra, L., and Collins, K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat. Cell. Biol., 4: 731-736, 2002.
11. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., and Anderson, K. C. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 20: 4519-4527, 2001.
12. Garg, A., and Aggarwal, B. B. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia (Baltimore), 16: 1053-1068, 2002.
13. Liang, S. H., and Clarke, M. F. The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal. Oncogene, 18: 2163-2166, 1999.
14. Heppner, C., Bilimoria, K. Y., Agarwal, S. K., Kester, M., Whitty, L. J., Guru, S. C., Chandrasekharappa, S. C., Collins, F. S., Spiegel, A. M., Marx, S. J., and Burns, A. L. The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene, 20: 4917-4925, 2001.
15. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dong, L., Castro, A., Palombella, V., Adams, J., and Anderson, K. C. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem., 277: 16639-16647, 2002.
16. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., and Anderson, K. C. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood, 99: 4079-4086, 2002.
17. Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J., and Siegel, D. S. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood, 93: 3044-3052, 1999.
18. Mitsiades, C. S., Mitsiades, N., Poulaki, V., Richardson, P. G., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Munshi, N., Treon, S. P., and Anderson, K. C. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 21: 5673-5683, 2002.
19. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., and Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
20. Xu, D., Zheng, C., Bergenbrant, S., Holm, G., Bjorkholm, M., Yi, Q., and Gruber, A. Telomerase activity in plasma cell dyscrasias. Br. J. Cancer, 84: 621-625, 2001.
21. Shiratsuchi, M., Muta, K., Abe, Y., Motomura, S., Taguchi, F., Takatsuki, H., Uike, N., Umemura, T., Nawata, H., and Nishimura, J. Clinical significance of telomerase activity in multiple myeloma. Cancer (Phila.), 94: 2232-2238, 2002.